- Home
- URGN
URGN
UroGen Pharma Ltd.
as 11-15-2024 4:00pm EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 547.1M | IPO Year: | 2017 |
| Target Price: | $44.50 | AVG Volume (30 days): | 456.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.60 - $20.70 | Next Earning Date: | 11-06-2024 |
| Revenue: | $89,363,000 | Revenue Growth: | 15.64% |
| Revenue Growth (this year): | 14.43% | Revenue Growth (next year): | 44.44% |
Stock Insider Trading Activity of UroGen Pharma Ltd. (URGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Jason Drew | URGN | General Counsel | Sep 9 '24 | Sell | $13.08 | 1,521 | $19,894.68 | 25,226 | |
| Schoenberg Mark | URGN | Chief Medical Officer | Sep 9 '24 | Sell | $13.08 | 859 | $11,235.72 | 145,091 |
Latest UroGen Pharma Ltd. News
URGN Breaking Stock News: Dive into URGN Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target
GuruFocus.com
10 days ago
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
Zacks
11 days ago
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
Business Wire
11 days ago
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
Business Wire
12 days ago
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
Business Wire
18 days ago
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
Business Wire
20 days ago
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Simply Wall St.
a month ago
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years
Compare URGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.